Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

TECH / Bio-Techne Corp / EATON VANCE MANAGEMENT - BIOTECHNECORP (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13 Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Bio-Techne Corp Common Stock (Title of Class of Securities) 09073M104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be fil

TECH / Bio-Techne Corp / Select Equity Group, L.P. - SCHEDULE 13G/A, AMENDMENT #1 (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bio-Techne Corp.  ______________________________________________ (Name of Issuer)   Common Stock ______________________________________________ (Title of Class of Securities) 09073M104 ______________________________________________ (CUSIP Number) December 31, 2017 ______________________________________________ (Date of Event Which Requires Filing of This Statement

TECH / Bio-Techne Corp / Select Equity Group, L.P. - SCHEDULE 13G/A, AMENDMENT #1 (Passive Investment)

2018-02-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bio-Techne Corp.  ______________________________________________ (Name of Issuer)   Common Stock ______________________________________________ (Title of Class of Securities) 09073M104 ______________________________________________ (CUSIP Number) December 31, 2017 ______________________________________________ (Date of Event Which Requires Filing of This Statement

TECH / Bio-Techne Corp / EATON VANCE MANAGEMENT - BIOTECHNECORP (Passive Investment)

2018-02-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13 Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Bio-Techne Corp Common Stock (Title of Class of Securities) 09073M104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be fil

TECH / Bio-Techne Corp / BROWN CAPITAL MANAGEMENT LLC - 3G/A (Passive Investment)

2018-02-14 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (AMENDMENT NO. _5_)*   Bio-Techne Corporation (Name of Issuer)   Common Stock, Par Value $0.01 (Title of Class of Securities)   09073M104 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of This Statement)   Check the appropriate box to de

TECH / Bio-Techne Corp / BROWN CAPITAL MANAGEMENT LLC - 3G/A (Passive Investment)

2018-02-14 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (AMENDMENT NO. _5_)*   Bio-Techne Corporation (Name of Issuer)   Common Stock, Par Value $0.01 (Title of Class of Securities)   09073M104 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of This Statement)   Check the appropriate box to de

TECH / Bio-Techne Corp / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
biotechnecorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 5 )*       Name of issuer:  Bio-Techne Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  09073M104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-

TECH / Bio-Techne Corp / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
biotechnecorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 5 )*       Name of issuer:  Bio-Techne Corp     Title of Class of Securities:  Common Stock     CUSIP Number:  09073M104     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule 13d-

TECH / Bio-Techne Corp FORM 10-Q (Quarterly Report)

2018-02-08 sec.gov
tech20171231_10q.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the quarterly period ended December 31, 2017, or   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from                      to                       Commission file number 0-17272    BIO-TECHNE CORPORATION (Exact name of regist

Bio-Techne (TECH) Q2 2018 Results - Earnings Call Transcript

2018-02-07 seekingalpha
Good morning and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2018. At this time, all participants have been placed in listen-only mode and the call will be opened for questions following management's prepared remarks. (1-0)

TECH / Bio-Techne Corp FORM 8-K (Current Report)

2018-02-06 sec.gov
tech20180205_8k.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549     FORM 8-K     Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 6, 2018     BIO-TECHNE CORPORATION (Exact Name of Registrant as Specified in its Charter)   Minnesota 0-17272 41-1427402 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.

Bio-Techne Corporation to Host Earnings Call

2018-02-06 accesswire
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / Bio-Techne Corporation (NASDAQ: TECH) will be discussing their earnings results in their Q2 Earnings Call to be held on February 6, 2018 at 9:00 AM Eastern Time. (4-0)

The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ

2018-01-24 zacks
Chicago, IL – January 24, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Anthera Pharmaceuticals, Inc. (ANTH - Free Report) , Bio-Techne Corporation (TECH - Free Report) , Exelixis, Inc. (EXEL - Free Report) , Paratek Pharmaceuticals, Inc. (123-0)

Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?

2018-01-23 zacks
Stryker Corporation’s (SYK - Free Report) fourth-quarter 2017 results are scheduled for release on Jan 30, 2018, after the market closes. In the said quarter, the company is expected to witness year-over-year revenue growth in all other business segments apart from Orthopedics, Medsurg and Neurotechnology and Spine. (85-0)


CUSIP: 09073M104